Thyroglobulin as early prognostic marker to predict remission at 18-24 months in differentiated thyroid carcinoma-Reference-Cited by-同舟云学术

Thyroglobulin as early prognostic marker to predict remission at 18-24 months in differentiated thyroid carcinoma

Published:2013-07-31 Issue:2 Volume:80 Page:301-306
ISSN:0300-0664
Container-title:Clinical Endocrinology
language:en
Short-container-title:Clin Endocrinol

Author:

González Cintia¹²,Aulinas Anna¹,Colom Cristina³,Tundidor Diana¹,Mendoza Lilian¹,Corcoy Rosa¹²⁴,Mato Eugenia²⁴,Alcántara Valeria¹,Urgell Rull Eulalia⁵,de Leiva Alberto¹²⁴

Affiliation:

1. Department of Endocrinology and Nutrition; Hospital Santa Creu i Sant Pau; Barcelona Spain

2. Biomedical Research Networking Centre on Bioengineering, Biomaterials & Nanomedicine: CIBER-BBN- EDUAB-HSP group; Barcelona Spain

3. Endocrinology Unit; Dos de Maig Hospital; Barcelona Spain

4. Department of Medicine; Universitat Autònoma de Barcelona; Barcelona Spain

5. Clinical Biochemistry Department; Hospital Santa Creu i Sant Pau; Barcelona Spain

Publisher

Wiley

Subject

Endocrinology, Diabetes and Metabolism,Endocrinology

Reference30 articles.

1. Factors determining the persistence or recurrence of well-differentiated thyroid cancer treated by thyroidectomy and/or radioiodine in the Boston Massachusetts area: a retrospective chart review;Leung;Thyroid Research,2011

2. Moleculars biomarkers involved in the tumour dedifferentiation process of thyroid carcinoma of epitherlial origin:prespectives;González;Endocrinología y Nutrición,2012

3. Uptodate on the molecular diagnosis of endocrine tumors: toward-omics-based personalized healthcare?;Weber;Journal of Clinical Endocrinology and Metabolism,2008

4. Molecular profiling related to poor prognosis in thyroid carcinoma. Combining gene expression data and biological information;Montero-Conde;Oncogene,2008

5. Is thyroglobulin the stronger indicator for progressive disease than the other conventional factors in same age patient groups with differentiated thyroid cancer?;Aras;Nuclear Medicine Communications,2007

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinicopathological features affecting the efficacy in 131I ablation therapy of papillary thyroid carcinoma with lymph node metastasis;Frontiers in Endocrinology;2024-07-17

2. Is Stimulated Thyroglobulin Before Radioiodine Therapy a Useful Tool in Predicting Response to Initial Therapy in Patients with Differentiated Thyroid Carcinoma?;Hormone and Metabolic Research;2024-05-21

3. Analysis of factors influencing the clinical outcome after surgery and 131I therapy in patients with moderate-risk thyroid papillary carcinoma;Frontiers in Endocrinology;2022-10-14

4. Combination of Stimulated Thyroglobulin and Antithyroglobulin Antibody Predicts the Efficacy and Prognosis of 131I Therapy in Patients With Differentiated Thyroid Cancer Following Total Thyroidectomy: A Retrospective Study;Frontiers in Endocrinology;2022-04-06

5. Comparing High and Low-Dose Radio-Iodine Therapy in Thyroid Remnant Ablation Among Intermediate and Low-Risk Papillary Thyroid Carcinoma Patients—Single Centre Experience;Dose-Response;2021-10